CN116115600A - Application of epstein in preparing hair loss preventing and hair growth promoting medicine - Google Patents

Abstract

The invention discloses an application of epstein and physiologically acceptable salts or solvates thereof in preparing anti-hair loss and hair growth medicines, belonging to the technical field of medicines. The medicine disclosed by the invention can be used for preventing and/or treating alopecia after chemotherapy and preventing and/or treating androgenic alopecia. The epstein provided by the invention is administrated through skin, has the advantages of controllable dosage, safety, no toxic or side effect, reduced irritation of medicine to gastrointestinal tract, rapid and definite effect, convenience in use, strong selectivity and the like, and has wide application prospects in the fields of pharmaceutical preparations, cosmetics, nursing products, cosmetics and the like.

Description

Application of epstein in preparing hair loss preventing and hair growth promoting medicine

Technical Field

The invention belongs to the technical field of medicines, and particularly relates to application of epstein in preparing anti-hair loss and hair-growing medicines, and further application of epstein in the fields of cosmetics, nursing products, beauty products and the like.

Background

Alopecia has become a "population anxiety" event, which refers to the phenomenon of hair loss. Hair does not grow endlessly, but undergoes three phases in the growth cycle of the follicle, telogen, anagen and catagen. Hair follicles under the skin are stimulated differently to respond differently during different stages of growth. The hair which is normally fallen off is in the withdrawal phase and the resting phase, and the hair which enters the withdrawal phase and the hair which enters the growing phase can continuously maintain the dynamic balance, so that the number of the hair can be kept normal even if the hair is lost every day. The head of a normal person has about 10 to 15 tens of thousands of hair follicles, and abnormal hair loss causes new hair to become thin and soft, eventually causing hair follicle atrophy. The serious abnormal alopecia can cause irreversible negative influence on the psychology of the patient, so that the patient is more sensitive to aging and is more inconceivable, and negative emotion is easy to generate to life, and the life quality is reduced. As society continues to develop and progress, the incidence of hair loss also continues to rise and a trend toward younger hair loss is presented.

Alopecia can be classified into physiological alopecia and pathological alopecia. Physiological alopecia can be classified into natural alopecia, infantile alopecia, senile alopecia, postpartum alopecia, etc. Pathological alopecia refers to abnormal or excessive hair loss, which is caused by a number of reasons, such as infection, endocrine disease, immune system disease, and nutritional deficiency. Two of the more common pathological alopecia are androgenic alopecia (Androgenetic alopecia, AGA) and post-Chemotherapy alopecia (CIA).

Eplerenone (Ipriflavone) having formula C ₁₈ H ₁₆ O ₃ Molecular weight: 280.32A naturally occurring phytoestrogen derivative, having the chemical name 7-isopropoxy-3-phenyl-4H-1-benzopyran-4-one, is a drug for the treatment and prevention of osteoporosis, which inhibits bone resorption while increasing calcitonin secretion and reducing blood calcium by estrogen-like action. It can enhance osteoblast proliferation, promote collagen formation and mineralization, and increase bone mass. In addition, it can significantly promote proliferation and osteogenic differentiation of periodontal ligament stem cells, promote cell regeneration (Han Yuanyuan. Effect of epstein on periodontal ligament stem cell proliferation and osteogenic differentiation and its mechanism research [ D ]]University of eastern mountain, 2019). The structural formula is as follows:

at present, the clinical medicine and the effective products for treating alopecia are still deficient, and only two medicines of Finasteride and Minoxidil are obtained in a batch on the global scale. Minoxidil is a potassium channel opener which treats androgenic alopecia by dilating scalp blood vessels and shortening telogen phase of hair follicle, but the effective rate is only 39% at most. Finasteride is a specific inhibitor of intracellular type II 5 alpha reductase in the process of metabolizing androgenic testosterone into dihydrotestosterone, and can reduce the content of androgenic substances in serum and tissues so as to inhibit the hair follicle of scalp from becoming smaller and reverse the hair loss process. However, the two medicines have general curative effects and obvious side effects. Therefore, there is an urgent need to find a safe and effective substance having anti-hair loss and hair growth activity.

Besides being used for treating and preventing osteoporosis, the Ipriflavone can also remarkably promote proliferation and osteogenic differentiation of periodontal ligament stem cells and promote cell regeneration. However, there is no document to report the application of epstein in hair loss and hair growth.

Disclosure of Invention

The invention aims to: the invention aims at overcoming the defects of the prior art and provides the application of epstein in preparing the anti-hair loss and hair growth medicament. The epstein disclosed by the invention is a safe and effective active substance for promoting hair growth, and can meet the effects of nursing, treatment and cosmetology. In particular, the invention provides the application of eplerenone in preparing the anti-alopecia and hair-growing pharmaceutical preparation; the application of epstein in preparing various cosmetics, nursing products and beauty products.

The technical scheme is as follows: the aim of the invention is achieved by the following technical scheme:

the invention provides an application of eplerenone and physiologically acceptable salts or solvates thereof in preparing hair loss prevention and hair growth promoting medicines.

The medicine is used for preventing and/or treating alopecia after chemotherapy; the medicament is used for preventing and/or treating androgenic alopecia.

Experiments show that: epstein can inhibit alopecia caused by chemotherapy, resist chemotherapy toxicity in alopecia caused by chemotherapy, and prevent alopecia. Hair loss reached peak at day 5 after cyclophosphamide injection, i.e. day 12 of administration, and hair growth scoring and hair growth weight measurement were performed at day 13 of administration. Compared with the model group, the epstein ointment group increases the hair growth score in a dose-dependent manner, and the effect is better than minoxidil at a medium-high concentration.

The epstein can inhibit androgen, stimulate the expression and synthesis of growth factors, and stimulate the proliferation and hair growth of hair follicle papilla cells, thereby preventing or treating androgenic alopecia. After androgen is smeared daily for modeling and is administrated for 14 days, compared with a model group, the eplerenone ointment group increases the hair length and weight in a dose-dependent manner, has significance, has better effect than minoxidil at medium and high concentration, can increase the expression level of related growth factor genes, stimulates the cell growth and promotes the cell survival, thereby promoting the hair growth.

The medicine has the effect of stimulating hair growth; the stimulation of hair growth includes accelerating the natural growth rate of hair, increasing hair length and hair weight, and promoting growth of existing hair in a healthy state.

Experiments show that: epstein has effects of promoting hair growth of hair-plucking mice. After hair removal and molding, the hair length and hair weight of the back hair of the mice were measured on day 14 of administration. Compared with the model group, the eplerenone ointment group increases the hair length in a dose-dependent manner, promotes the hair growth, and has better effect than the positive drug minoxidil at high concentration.

When preparing the medicine for treating alopecia related diseases, using eplercanine as an active ingredient, and applying the medicine to a pharmaceutical preparation; the pharmaceutical preparation is applied to preventing, nursing and treating the rare hair and the alopecia and promoting the hair health and growth; the medicine comprises epstein and pharmaceutically acceptable carriers or auxiliary materials.

The pharmaceutically acceptable carrier (e.g., biocompatible material) optionally includes, for example, surfactants, excipients, humectants, emulsifiers, suspending agents, salts or buffers for regulating osmotic pressure, colorants, fragrances, stabilizers, bactericides, preservatives, or other conventional supplements.

The medicine is in the form of cream, patch, ointment, cream preparation, gel or spray.

The medicament may also be an oral formulation. Further, the oral preparation is a tablet, a granule, a capsule, an oral liquid preparation, a pill, a suspension or a dripping pill.

In the treatment of alopecia related diseases, eplerenone is used as active ingredient, and can be topically applied via skin, such as cream, patch, ointment, cream, gel, spray, etc., or orally administered (i.e. oral preparation), such as tablet, granule, capsule, oral liquid, pill, suspension, dripping pill, etc.

The epstein and its physiologically acceptable salt or solvate account for 0.1-10wt% of the total weight of the preparation.

The medicament of the invention can also be used in cosmetics, nursing products or beauty products. The cosmetic, nursing product or beauty product takes epstein as an active ingredient.

The cosmetic, nursing product or beauty product can be selected from shampoo, hair conditioner, hair care essence, hair care oil, hair care emulsion, scalp cream, hair care gel, hair spray, hair care film, eyebrow nursing liquid, etc.

The invention is found by research: epstein stimulates hair to grow up and reduces the risk of hair loss under normal physiological conditions, including accelerating the natural growth rate of hair, increasing hair length and hair weight, and promoting the growth of existing hair in a healthy state; epstein can inhibit androgen, stimulate the expression and synthesis of growth factors, and stimulate proliferation and hair growth of hair follicle papilla cells, thereby preventing or treating androgenic alopecia; epstein is effective in resisting chemotherapy toxicity and preventing alopecia in alopecia caused by chemotherapy.

The beneficial effects are that:

(1) The eplerenone related by the invention can be used as an active ingredient, is applied to preventing alopecia and promoting hair growth, exploits the new application of the eplerenone, and provides a new choice for preparing the alopecia preventing and hair growth promoting drugs. The epstein provided by the invention is administrated through skin, has the advantages of controllable dosage, safety, no toxic or side effect, reduced irritation of medicine to gastrointestinal tract, rapid and definite effect, convenience in use, strong selectivity and the like, and has wide application prospects in the fields of pharmaceutical preparations, cosmetics, nursing products, cosmetics and the like.

(2) In the aspect of preventing and treating the alopecia related to the invention, the efficacy of the eplerenone is better than that of minoxidil approved by FDA, and the eplerenone enables ideal safe and effective active substances for preventing and treating alopecia in view of the defects of general curative effect and obvious side effect of other medicaments for treating alopecia at present.

Drawings

FIG. 1 is a graph showing the effect of epstein on hair length in a model mouse with natural hair growth.

Figure 2 is the effect of epstein on hair weight in a model mouse with natural hair growth.

Figure 3 shows the effect of epstein on hair growth in a pattern of hair loss following chemotherapy.

Figure 4 is the effect of epstein on hair growth in post-chemotherapy alopecia mice.

Figure 5 is the effect of epstein on hair weight in post-chemotherapy alopecia mice.

Figure 6 shows the effect of epstein on hair length in androgenic alopecia mice.

Figure 7 is the effect of epstein on hair weight in androgenic alopecia mice.

FIG. 8 shows changes in expression of skin growth factor genes in epiflavone in androgenic alopecia mice.

Detailed Description

The technical scheme of the present invention is described in detail below through specific examples, but the scope of the present invention is not limited to the examples.

The specific techniques or conditions are not identified in the examples and are described in the literature in this field or are carried out in accordance with the product specifications. The reagents or equipment used were conventional products available for purchase through regular channels, with no manufacturer noted.

The experimental methods in the following examples are conventional methods unless otherwise specified. The test materials used in the examples described below, unless otherwise specified, are all commercially available products.

Unless otherwise indicated, "%" in the examples refers to mass percent.

Example 1 efficacy evaluation experiment of epstein on the model of Natural pilatory growth in C57BL/6J mice

1. Experimental animal

The experimental animals are male C57BL/6J,8-9 weeks old, and 20-24g in weight, and are purchased from the university of Yangzhou comparative medical center. C57BL/6J mice are fed under normal conditions, the temperature is 25+/-2 ℃, the humidity is 50% -70%, illumination and darkness are alternately carried out for 12 hours, corn cob padding can be replaced every two days, and experiments are started after the corn cob padding is adapted to the feeding environment for 7 days.

2. Pharmaceutical formulation

4% chloral hydrate: 0.8g of chloral hydrate is weighed and poured into a 20ml centrifuge tube, 19.2ml of physiological saline is added, and the chloral hydrate is fully and uniformly dissolved to prepare 4% chloral hydrate solution for use.

The external emulsifiable paste (concentration: 0.5%, 2.5%, 5%) of the epstein is prepared from the following raw materials:

50, 250, 500 parts of epstein, 1000 parts of stearic acid, 200 parts of glyceryl stearate, 200 parts of beeswax, 200 parts of palm oil, 600 parts of butanediol, 200 parts of ethanol, 4800 parts of water and 2 parts of triethanolamine. The external cream of the invention is prepared according to the raw material components:

(1) Weighing stearic acid, glyceryl stearate, beeswax and palm oil in proportion, heating in water bath to melt, filtering, and preserving at 70-80deg.C;

(2) Proportionally weighing butanediol, ethanol, water and triethanolamine, adding into the above solution, heating in water bath under stirring, and emulsifying for 10-20 min under heat preservation;

(3) Adding weighed eplerenone raw materials, stirring the raw materials and the cream while adding until the raw materials and the cream are uniformly mixed, and obtaining 0.5%, 2.5% and 5% of eplerenone external cream.

Epstein oral suspension formulation: the dosage is 100mg/kg, before use, the powder is dissolved by 0.5% CMC-Na, vortex centrifugation is carried out, and after complete suspension, the powder is used for oral gavage of mice.

3. Natural alopecia model establishment

(1) Experimental principle:

the hair growth arrest of C57BL/6 mice of 8-9 weeks old is in resting stage, and a natural hair growth model can be constructed, all resting stage hairs are plucked out by waxed paper, the development of highly synchronous anagen hair follicles is induced, and the hair follicles are morphologically indistinguishable from spontaneously formed anagen hair follicles.

(2) The specific operation is as follows:

after weighing the mice, 4% chloral hydrate was injected intraperitoneally at a dose of 10 μl/g b.w. (body weight). After the anesthesia of the mice is completed, the back hair is shaved by a shaver, the cut 5.20cm x 2.60cm dehairing waxed paper is covered by hands, the mice are attached to the tail parts from behind the ears along the hair growth direction of the mice, the mice are covered by hands for at least 2 minutes, the legs are grasped by the left hand, the back legs are placed on the tiger mouth in the front direction, the tail is pressed by the thumb, the right hand reverse hair is rapidly torn off the wax paper from the tail parts, and the back is rubbed by the waxed wet paper.

The 48 male C57BL/6J mice were randomly divided into a model group, an oral epstein group, a 0.5% epstein ointment group (0.5% epstein), a 2.5% epstein ointment group (2.5% epstein), a 5% epstein ointment group (5% epstein), and a 2.5% minoxidil group, each group of 8 animals.

4. Experimental evaluation of efficacy of epstein on natural hair growth of mice with natural alopecia

The administration was started 1 day after depilation, 1 time a day, and 13 days continuously. The commercial minoxidil tincture concentration was 5%, and the same volume of absolute ethanol was added to dilute to 2.5% and the dose was 200 μl each. The control group was given a blank cream without drug; the concentration of the epstein ointment group is 0.5%, 2.5% and 5%, the dosage is 0.2 g/dose, and about 0.2g of the ointment is dipped by a cotton swab and smeared on the dehairing area when the ointment is used for each administration. The oral administration dosage of the eplerenone is 100mg/kg, and the administration mode is stomach-lavage oral administration.

On day 14 after administration, the laboratory mice were intraperitoneally injected with 10 μl/g of b.w.4% chloral hydrate, after the mice were anesthetized and stabilized, 6 fixed site hairs on the backs of the mice were carefully nipped with forceps, about 10 hairs per forceps were taken, placed on clean white paper, and the length was measured with vernier calipers and the longest value thereof was selected as the recorded value, and the whole measurement process was repeated 2 times.

After the measurement of the hair length is completed, the grown hair in the depilating area is shaved by a shaver, collected by weighing paper, and the weight of the hair is weighed by an electronic balance of ten parts per million.

5. Experimental results

The hair length results are shown in figure 1, and compared with the model group, the epstein ointment group increases the hair length in a dose-dependent manner, promotes the hair growth, and has better effect than the positive drug minoxidil at high concentration. Oral epstein groups also increased hair length but were not significant.

The hair weight results are shown in figure 2, and the epstein ointment group increased hair weight in a dose-dependent manner compared with the model group, and the effect of the epstein ointment group is superior to that of the positive drug minoxidil at the medium-high concentration. Oral epstein groups also increased hair weight but were not significant.

From the above, it can be seen that the eplerenone has a remarkable effect of promoting hair growth in the hair growth process of mice, and the application of the ointment has more remarkable effect than the oral administration, and the curative effect is better than minoxidil.

Example 2 efficacy evaluation experiment of epstein on C57BL/6 mice chemotherapy alopecia model

1. Experimental animal

The experimental animals were the same as in example 1.

2. Pharmaceutical formulation

Preparation of 4% chloral hydrate, epstein ointment, epstein oral suspension was the same as in example 1.

8mg/ml cyclophosphamide injection (Androgen): 0.2g cyclophosphamide was dissolved in 25ml physiological saline, centrifuged by vortexing, and the mice were injected intraperitoneally after complete dissolution.

3. Modeling of hair loss model by chemotherapy

(1) Experimental principle:

back hair is removed from 8-9 weeks old C57 male mice, all hair follicle in the hair removal area enter into growth VI phase on 7 th day after hair removal, 80mg/kg cyclophosphamide is injected into the abdominal cavity once, and rapid growth hair follicle apoptosis cells are induced to increase, so that chemotherapy alopecia occurs to the new hair of the mice.

(2) The specific operation is as follows:

the depilation method was the same as in example 1.

56 male C57BL/6J mice were randomly assigned to 8 groups of control, model, oral, 0.5% eplerenone ointment (0.5% eplerenone), 2.5% eplerenone ointment (2.5% eplerenone), 5% eplerenone ointment (5% eplerenone), and 2.5% minoxidil.

On day 8 after depilation, the hair was brought into phase VI of growth, and 0.1ml/10g B.W.80mg/kg cyclophosphamide injection was intraperitoneally injected according to body weight, and the control group was injected with solvent physiological saline. On day 5 after cyclophosphamide injection, hair loss reached the most severe period.

4. Efficacy evaluation experiment of eplerenone in chemotherapy alopecia model

The administration was started 1 day after depilation, 1 time a day, and the administration was continued for 12-13 days, and the experiment was terminated depending on the condition of hair loss. The commercial minoxidil tincture concentration was 5%, and the same volume of absolute ethanol was added to dilute to 2.5% and the dose was 200 μl each. The control and model groups were given blank cream without drug; the concentration of the epstein ointment group is 0.5%, 2.5% and 5%, the dosage is 0.2 g/dose, and about 0.2g of the ointment is dipped by a cotton swab and smeared on the dehairing area when the ointment is used for each administration. The oral administration dosage of the eplerenone is 100mg/kg, and the administration mode is stomach-lavage oral administration.

On day 12 of administration, hair loss reached the most severe period, on day 13, mice were intraperitoneally injected with 10 μl/g of b.w.4% chloral hydrate, and after mice were anesthetized, the back skin condition and hair growth of each group of mice were recorded by photographing under standard conditions and scored for statistics. Scoring criteria: the remaining hair area is a proportion of the total area of the depilating area.

After finishing the hair growth scoring, carefully forceps the 6 fixed site hairs on the back of the mouse with forceps, taking about 10 hairs per forceps, placing the hairs on clean white paper, measuring the length by using a vernier caliper, selecting the longest value as a recorded value, and repeating the whole measuring process for 2 times.

After the measurement of the hair length is completed, the grown hair in the depilating area is shaved by a shaver, collected by weighing paper, and the weight of the hair is weighed by an electronic balance of ten parts per million.

5. Experimental results

The hair growth score results are shown in fig. 3, and the model group growth score is significantly reduced compared with the blank group, proving that the model was successful. Compared with the model group, the epstein ointment group increases the hair growth score in a dose-dependent manner, and the effect is better than minoxidil at a medium-high concentration. Oral epstein groups also increased hair growth scores but were not significant. Experiments show that epstein can inhibit alopecia caused by chemotherapeutics on appearance.

The results of the hair length and the hair weight are shown in fig. 4 and 5, and compared with a blank control group, the hair length and the hair weight of the model group are obviously reduced, so that the model is proved to be successful. Compared with the model group, the epstein ointment group increases the hair length and weight in a dose-dependent manner, has significance, and has better effect than minoxidil at medium and high concentration. Oral epstein groups also increased hair length and weight but were not significant.

The results of the above experiments show that epstein can inhibit alopecia caused by chemotherapy drugs.

Example 3 efficacy evaluation experiment of epstein on C57BL/6 mice androgen alopecia model

1. Experimental animal

The experimental animals were the same as in example 1.

2. Pharmaceutical formulation

Preparation of 4% chloral hydrate, epstein ointment, epstein oral suspension was the same as in example 1.

0.25% testosterone solution: accurately weighing 0.25g testosterone powder, adding 80ml absolute ethanol solution and 20ml propylene glycol solution, uniformly dissolving, and storing in a refrigerator at 4 ℃ for standby.

Blank solvent: 40ml of absolute ethanol solution and 10ml of propylene glycol solution are uniformly mixed to form 50ml of blank solvent, and the blank solvent is stored in a refrigerator at 4 ℃ for standby.

3. Androgenic alopecia model building mould

(1) Experimental principle:

the C57BL/6 mice androgen alopecia model is similar to the natural hair growth and dehairing mouse model in the earlier stage of establishment, and the C57 male mice with the age of 8-9 weeks are subjected to the next day after back hair is removed, and are subjected to modeling by using a testosterone solution with the concentration of 0.25% every day, so that the hair growth is inhibited.

(2) The specific operation is as follows:

the depilation method was the same as in example 1.

56 male C57BL/6J mice were randomly assigned to 8 groups of control, model, oral, 0.5% eplerenone ointment (0.5% eplerenone), 2.5% eplerenone ointment (2.5% eplerenone), 5% eplerenone ointment (5% eplerenone), and 2.5% minoxidil.

Starting on day 1 after dehairing, a molding agent is smeared on the back of the dehairing area of the mice, 200 μl/mouse, and molding is carried out for 14 days 1 time a day. The blank control group was coated with a blank solvent and the remaining groups were coated with a 0.25% testosterone solution.

4. Efficacy evaluation experiment of eplerenone in androgen alopecia model

After daily molding, after the molding agent is absorbed, the back of the experimental mice is smeared and administrated for 1 time a day, and the administration is continued for 14 days. The commercial minoxidil tincture concentration was 5%, and the same volume of absolute ethanol was added to dilute to 2.5% and the dose was 200 μl each. The control and model groups were given blank cream without drug; the concentration of the epstein ointment group is 0.5%, 2.5% and 5%, the dosage is 0.2 g/dose, and about 0.2g of the ointment is dipped by a cotton swab and smeared on the dehairing area when the ointment is used for each administration. The oral administration dosage of the eplerenone is 100mg/kg, and the administration mode is stomach-lavage oral administration.

On day 15 after administration, the laboratory mice were intraperitoneally injected with 10 μl/g of 4% chloral hydrate, after the mice were anesthetized and stabilized, 6 fixed-site hairs on the backs of the mice were carefully nipped with forceps, about 10 hairs were nipped each time, placed on clean white paper, and the length was measured with a vernier caliper and the longest value thereof was selected as the recorded value, and the whole measurement process was repeated 2 times.

After the measurement of the hair length is completed, the grown hair in the depilating area is shaved by a shaver, collected by weighing paper, and the weight of the hair is weighed by an electronic balance of ten parts per million.

Taking back skin tissue of a mouse, extracting RNA, carrying out reverse transcription to obtain cDNA, carrying out qPCR amplification by adopting a SYBR Green dye method, calculating according to a Ct value by adopting a delta Ct method, and analyzing the change of the expression level of a growth factor related gene, wherein the related primer sequences are shown in Table 1:

TABLE 1RT-qPCR primer sequences

The primers of the invention were purchased from Shanghai organisms.

The relevant qPCR reaction system is shown in table 2:

TABLE 2RT-qPCR reaction System

The relevant qPCR reaction procedure is shown in table 3:

TABLE 3qPCR reaction procedure

5. Experimental results

The results of the hair length and the hair weight are shown in fig. 6 and 7, and compared with a blank control group, the hair length and the hair weight of the model group are obviously reduced, so that the model is proved to be successful. Compared with the model group, the epstein ointment group increases the hair length and weight in a dose-dependent manner, has significance and has better effect than minoxidil at medium and high concentration. Oral epstein groups also increased hair length and weight but were not significant in hair weight.

The experimental results show that epper Huang Tongneng relieves the alopecia caused by androgens.

The results of the expression levels of the skin growth factor genes are shown in fig. 8, and compared with the blank control group, the expression levels of the IGF1 and VEGF, EGF, HGF, KGF genes in the model group are remarkably reduced, and the expression levels of the growth factor genes in the epstein administration group are remarkably improved, so that the growth of cells, the survival of the cells and the hair growth can be stimulated.

As described above, although the present invention has been shown and described with reference to certain preferred embodiments, it is not to be construed as limiting the invention itself. Various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims.

Claims (10)

1. Use of eplerenone and its physiologically acceptable salts or solvates in the preparation of a medicament for preventing alopecia and promoting hair growth.

2. The use according to claim 1, wherein the medicament is for preventing and/or treating alopecia after chemotherapy; the medicament is used for preventing and/or treating androgenic alopecia.

3. The use according to claim 1 or 2, wherein the medicament has the effect of stimulating hair growth; the stimulation of hair growth includes accelerating the natural growth rate of hair, increasing hair length and hair weight, and promoting growth of existing hair in a healthy state.

4. The use according to claim 1 or 2, wherein the medicament is for use in a pharmaceutical formulation; the pharmaceutical preparation is applied to preventing, nursing and treating the rare hair and the alopecia and promoting the hair health and growth; the pharmaceutical preparation further comprises epstein and pharmaceutically acceptable carriers or auxiliary materials.

5. The use according to claim 4, wherein the medicament is in the form of a cream, a patch, an ointment, a cream, a gel or a spray.

6. The use according to claim 4, wherein the medicament is an oral formulation.

7. The use according to claim 6, wherein the oral formulation is a tablet, granule, capsule, oral liquid formulation, pill, suspension or drop pill.

8. The use according to claim 4, wherein the epstein and its physiologically acceptable salts or solvates constitute 0.1 to 10 wt.% of the total weight of the formulation.

9. The use according to claim 1, wherein the medicament is for use in cosmetics, nursing or cosmetology.

10. The use according to claim 9, characterized in that the cosmetic, care or make-up is selected from the group consisting of shampoos, conditioners, hair extracts, hair oils, hair emulsions, scalp creams, hair gels, hair sprays, hair films or eyebrow lotions.

Images